Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia

Pei Huang,Yuan-Yuan Li,Jung E. Park,Ping Huang,Qin Xiao,Ying Wang,Sheng Chen,Sheng-Di Chen,Jun Liu,Yi-Wen Wu
DOI: https://doi.org/10.1017/cjn.2021.42
2022-01-01
Abstract:We investigated the effects of botulinum toxin on gait in Parkinson's disease (PD) patients with foot dystonia. Six patients underwent onabotulinum toxin A injection and were assessed by Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), visual analog scale (VAS) of pain, Timed Up and Go (TUG), Berg Balance Test (BBT), and 3D gait analysis at baseline, 1 month, and 3 months. BFMDRS (p = 0.002), VAS (p = 0.024), TUG (p = 0.028), and BBT (p = 0.034) were improved. Foot pressures at Toe 1 (p = 0.028) and Midfoot (p = 0.018) were reduced, indicating botulinum toxin's effects in alleviating the dystonia severity and pain and improving foot pressures during walking in PD.
What problem does this paper attempt to address?